J147
NootropicsPhase 2Also known as: J-147, J 147, Curcumin-derived phenyl hydrazide, N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-((3-methoxyphenyl)methylideneamino)acetamide
J147 is a synthetic phenyl hydrazide derived from curcumin, made at the Salk Institute for Biological Studies. It came out of a screening strategy that deliberately avoided the amyloid hypothesis: instead of selecting for affinity to one disease-specific target, the group screened compounds against several cell culture models of age-associated pathology.
Overview
At A Glance
The molecular target of J147 is the mitochondrial alpha-F1-ATP synthase subunit ATP5A. Modest inhibition of ATP synthase increases intracellular calcium, which produces sustained calcium/calmodulin-dependent protein kinase kinase beta (CAMKK2) dependent activation of the AMPK and…
Overview
J147 is a synthetic phenyl hydrazide derived from curcumin, made at the Salk Institute for Biological Studies. It came out of a screening strategy that deliberately avoided the amyloid hypothesis: instead of selecting for affinity to one disease-specific target, the group screened compounds against several cell culture models of age-associated pathology. The molecule that emerged was orally active, facilitated memory in normal rodents and prevented the loss of synaptic proteins and cognitive decline in a transgenic Alzheimer disease mouse model (PMID: 22194796). Unlike the racetams on this site, J147 was never a marketed drug anywhere and has always been an investigational compound; consumer-facing material is sold as a research chemical. The molecular target was identified in 2018 as the mitochondrial alpha-F1-ATP synthase subunit ATP5A. Modest inhibition of ATP synthase raises intracellular calcium, which produces sustained CAMKK2-dependent activation of the AMPK and mTOR pathway, a longevity mechanism conserved across species. In mice, J147 prevented age-associated drift in the hippocampal transcriptome and plasma metabolome, and it extended lifespan in Drosophila (PMID: 29316249). Related work found that J147 and a second Salk compound increased acetyl-CoA levels by inhibiting acetyl-CoA carboxylase 1 and reduced cognitive decline and markers of aging in rapidly aging SAMP8 mice (PMID: 31742554). The strongest preclinical result is the treatment design rather than the prevention design. Twenty-month-old APP/PS1 transgenic mice, at a stage where pathology was already advanced, were fed J147 for three months and showed improved spatial navigational memory in the water maze and rescued contextual fear conditioning, alongside induction of nerve growth factor and brain-derived neurotrophic factor (PMID: 23673233). Efficacy has also been reported in rat models of ischemic stroke, where J147 reduced infarct volume and reduced tissue plasminogen activator associated brain hemorrhage (PMID: 35309561), in mouse traumatic brain injury (PMID: 39245209) and in mouse diabetic neuropathy (PMID: 29122628). The animal safety package is unusually detailed for a compound at this stage. Single doses of 2 g/kg in rats and mice produced no acute toxicity, and the Ames test, the hERG assay and CYP3A4 assays were all negative (PMID: 23673233). Because phenyl hydrazides can in principle be metabolized to carcinogenic aromatic amines or hydrazines, the group specifically tested this and found that J147 is not metabolized to those products in human or mouse microsomes or in mouse plasma (PMID: 23582448). A separate panel in a rat hepatoma line put the sustained concentration expected to produce toxicity at about 90 micromolar (PMID: 25364619). Human data are the gap. A phase 1 randomized, double-blind, placebo-controlled single ascending dose study in 64 healthy young and elderly volunteers, sponsored by Abrexa Pharmaceuticals, completed in February 2020 with safety and pharmacokinetics as endpoints, and no results have been posted or published (NCT03838185). A phase 2 study of intravenous J147 combined with endovascular therapy in acute ischemic stroke began recruiting in July 2026 (NCT07430917). J147 is not approved anywhere and remains a research-use-only compound in the United States market.
Potential Research Fields
Chemical Information
IUPAC Name
Not yet available
CAS Number
1146963-51-0
Molecular Formula
C18H17F3N2O2
Molecular Mass
350.34 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
None established in humans. The published phase 1 protocol excluded volunteers with clinically significant cardiovascular, neurological, psychiatric, hepatic or renal disease, required them to avoid grapefruit and Seville oranges, and excluded anyone who had taken known hepatic or renal clearance altering agents in the preceding 30 days, which indicates sponsor concern about metabolic interactions (NCT03838185). Mechanism-based caution: the target is the mitochondrial alpha-F1-ATP synthase and the compound works by modest inhibition of that enzyme (PMID: 29316249), so it is a metabolic intervention rather than a neutral supplement, and cell work shows mitochondrial effects at high concentrations (PMID: 25364619). No pregnancy, lactation or drug interaction data exist in humans.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$99.99
—
1
1
capsule
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
J-147 capsules (60) | capsule | 60 capsules● In Stock | $99.99BEST | — | — |
Tracking since Sep 7, 2026 · 1 data point
Vendors Selling J147
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View All9-Me-BC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].
Aniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Cyclazodone
NootropicsPreclinicalCyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
View Full Dosage Guide →
Protocols, calculator & safety for J147
Research Score
0 PubMed studies
Quality Indicators
Data Completeness
63%Quick Facts
Half-Life
Not established in humans; the phase 1 study measured terminal half-life but has not reported results (NCT03838185). After oral dosing in mice, half-life was about 1.5 hours in plasma and 2.5 hours in brain, with oral bioavailability calculated at 28 percent and a brain to blood ratio of about 0.5 (PMID: 23673233).
Molecular Weight
350.34 g/mol
Administration
Oral, Intravenous infusion
CAS Number
1146963-51-0
Trial Phase
Phase 2
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is J147 used for in research?
J147 is a synthetic phenyl hydrazide derived from curcumin, made at the Salk Institute for Biological Studies. It came out of a screening strategy that deliberately avoided the amyloid hypothesis: instead of selecting for affinity to one disease-specific target, the group screened compounds against several cell culture models of age-associated pathology. The molecule that emerged was orally active, facilitated memory in normal rodents and prevented the loss of synaptic proteins and cognitive decline in a transgenic Alzheimer disease mouse model (PMID: 22194796). Unlike the racetams on this site, J147 was never a marketed drug anywhere and has always been an investigational compound; consumer-facing material is sold as a research chemical.
The molecular target was identified in 2018 as the mitochondrial alpha-F1-ATP synthase subunit ATP5A. Modest inhibition of ATP synthase raises intracellular calcium, which produces sustained CAMKK2-dependent activation of the AMPK and mTOR pathway, a longevity mechanism conserved across species. In mice, J147 prevented age-associated drift in the hippocampal transcriptome and plasma metabolome, and it extended lifespan in Drosophila (PMID: 29316249). Related work found that J147 and a second Salk compound increased acetyl-CoA levels by inhibiting acetyl-CoA carboxylase 1 and reduced cognitive decline and markers of aging in rapidly aging SAMP8 mice (PMID: 31742554).
The strongest preclinical result is the treatment design rather than the prevention design. Twenty-month-old APP/PS1 transgenic mice, at a stage where pathology was already advanced, were fed J147 for three months and showed improved spatial navigational memory in the water maze and rescued contextual fear conditioning, alongside induction of nerve growth factor and brain-derived neurotrophic factor (PMID: 23673233). Efficacy has also been reported in rat models of ischemic stroke, where J147 reduced infarct volume and reduced tissue plasminogen activator associated brain hemorrhage (PMID: 35309561), in mouse traumatic brain injury (PMID: 39245209) and in mouse diabetic neuropathy (PMID: 29122628).
The animal safety package is unusually detailed for a compound at this stage. Single doses of 2 g/kg in rats and mice produced no acute toxicity, and the Ames test, the hERG assay and CYP3A4 assays were all negative (PMID: 23673233). Because phenyl hydrazides can in principle be metabolized to carcinogenic aromatic amines or hydrazines, the group specifically tested this and found that J147 is not metabolized to those products in human or mouse microsomes or in mouse plasma (PMID: 23582448). A separate panel in a rat hepatoma line put the sustained concentration expected to produce toxicity at about 90 micromolar (PMID: 25364619).
Human data are the gap. A phase 1 randomized, double-blind, placebo-controlled single ascending dose study in 64 healthy young and elderly volunteers, sponsored by Abrexa Pharmaceuticals, completed in February 2020 with safety and pharmacokinetics as endpoints, and no results have been posted or published (NCT03838185). A phase 2 study of intravenous J147 combined with endovascular therapy in acute ischemic stroke began recruiting in July 2026 (NCT07430917). J147 is not approved anywhere and remains a research-use-only compound in the United States market.
What forms does J147 come in?
J147 is available in capsule form.
How much does J147 cost?
Prices start at $99.99 across 1 verified vendor.
How do I compare J147 vendors?
Compare prices, payment methods, shipping, and COA scores across 1 vendor.
Research Tools
Related Compounds
View All9-Me-BC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].
Aniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Cyclazodone
NootropicsPreclinicalCyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.